Read by QxMD icon Read

Nicotinamide hemodialysis

Yong Zhang, Tean Ma, Pan Zhang
BACKGROUND: Recent evidence has shown that nicotinamide treatment may have an impact on phosphorus metabolism in hemodialysis patients. Nevertheless, the treatment remains controversial. This study aimed to precisely estimate the efficacy and safety of nicotinamide on phosphorus, calcium and iPTH in hemodialysis patients. METHODS: We searched numerous information sources regarding randomized controlled trials (RCTs) of nicotinamide treatment in hemodialysis patients, including PubMed, EMBASE, and the Cochrane Library...
October 2018: Medicine (Baltimore)
Toshimitsu Niwa
Indoxyl sulfate is a uremic toxin, and cannot be removed efficiently by hemodialysis due to its protein-binding. Indoxyl sulfate induces cellular dysfunction by producing reactive oxygen species (ROS) such as superoxide by activating nicotinamide adenine dinucleotide phosphate oxidase, and by activating aryl hydrocarbon receptor through its uptake via organic anion transporters (OAT1 and OAT3). Indoxyl sulfate shows toxic effects on a variety of cells such as renal proximal tubular cells, glomerular mesangial cells, vascular smooth muscle cells, vascular endothelial cells, cardiomyocytes, cardiac fibroblasts, monocytes, osteoblasts, osteoclasts, and myocytes...
June 2017: Panminerva Medica
Radwa El Borolossy, Lamia Mohamed El Wakeel, Ihab El Hakim, Nagwa Sabri
BACKGROUND: Hyperphosphatemia is a common problem in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the development of secondary hyperparathyroidism and cardiovascular complications. Nicotinamide (NAM) has been shown in some studies to inhibit intestinal and renal sodium/phosphorus co-transporters and reduce serum phosphorus levels. We have therefore evaluated the efficacy and safety of NAM as adjunctive therapy to calcium-based phosphate binders to control hyperphosphatemia in hemodialysis patients...
February 2016: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
Ivana Celap, Ana-Maria Simundic, Nora Nikolac, Marijana Miler, Ivana Zec, Karmela Altabas, Sinisa Sefer
BACKGROUND: Cardiovascular events are a major cause of death in patients with end-stage renal disease. Endothelial dysfunction represents a key event in atherosclerosis development and has been implicated in the pathophysiology of different forms of cardiovascular disease, including chronic kidney disease. In recent years, visfatin, a ubiquitous adipokine, has been described as a potent marker of endothelial inflammation and dysfunction. The aim of the study was to investigate the association of visfatin with well-known markers of inflammation and endothelial dysfunction...
2013: Clinical Laboratory
Theodoros Eleftheriadis, Georgios Pissas, Maria Remoundou, Georgia Antoniadi, Vassilios Liakopoulos, Ioannis Stefanidis
BACKGROUND: Studies detected an association between visfatin and markers of iron metabolism in patients with insulin resistance. In this study, such a relation was evaluated in hemodialysis (HD) patients. Also relations between visfatin and hepcidin, demands for recombinant human erythropoietin (rHuEpo), inflammation, and situations characterized by insulin resistance were evaluated. METHODS: After a four-week washout period from iron treatment, 33 HD patients and 20 healthy volunteers enrolled in the study...
2013: Renal Failure
Amanda Rennick, Rabih Kalakeche, Lindsey Seel, Brian Shepler
Phosphate binders have traditionally been used to treat hyperphosphatemia, a common complication in patients with end stage renal disease (ESRD). New evidence suggests that nicotinic acid and its metabolites may effectively decrease phosphorus absorption in the gastrointestinal tract, thereby reducing serum phosphorus concentrations. We conducted a literature search to identify studies of patients with ESRD on dialysis that evaluated the role of niacin and related compounds in decreasing serum phosphorus levels...
June 2013: Pharmacotherapy
Ouppatham Supasyndh, Bancha Satirapoj, Pornanong Aramwit, Duangkamol Viroonudomphol, Amnart Chaiprasert, Vipa Thanachatwej, Supat Vanichakarn, Joel D Kopple
BACKGROUND AND OBJECTIVES: Sarcopenia is common in hemodialysis patients. This study examined whether the anabolic steroid oxymetholone improves muscle mass and handgrip strength in hemodialysis patients and possible mechanisms that might engender such changes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-three eligible hemodialysis patients were randomly assigned to ingest oxymetholone or placebo for 24 weeks. Body composition, handgrip strength, and quality of life were measured during the study...
February 2013: Clinical Journal of the American Society of Nephrology: CJASN
Jun-Neng Roan, Shih-Yuan Fang, Shih-Wei Chang, Chih-Hsin Hsu, Chein-Chi Huang, Meng-Hsuan Chiou, Yu-Chuan Tsai, Chen-Fuh Lam
OBJECTIVE: This study investigates the pathogenesis of arteriovenous (AV) fistula failure in patients with diabetes mellitus (DM) and tests the vascular protective effect of rosuvastatin on the fistulous communication of diabetic rats. METHODS: DM was induced in rats by a single injection of streptozotocin. One week later, a fistula was created in the descending aorta and the adjacent inferior vena cava (aortocaval [AC] fistula). Rats were then randomly assigned to receive placebo or rosuvastatin (15 mg/kg/d) in chow for 2 weeks...
November 2012: Journal of Vascular Surgery
Vladimír Teplan, Jan Malý, Robert Gürlich, Vladimír Teplan, Michal Kudla, Jan Pit'ha, Jaroslav Racek, Martin Haluzík, Ladislav Senolt, Milena Stollová
Our prospective study analyzed selected adipocytokines: adiponectin (ADPN), leptin, visfatin, and asymmetric dimethylarginine (ADMA) in the plasma of renal transplant recipients previously treated by peritoneal dialysis and hemodialysis. A total of 70 patients were on follow-up for 12 months after transplantation. Of these, 30 patients (group I) developed obesity, and 40 patients were nonobese (group II). All were receiving standard immunosuppressive therapy (cyclosporine A or tacrolimus and mycophenolate mofetil, with prednisone added in the early posttransplant period) and did not differ statistically in HLA typing, age, sex, duration of previous dialysis, history of cardiovascular disease, and rate of rejection episodes...
January 2012: Journal of Renal Nutrition
Bolesław Rutkowski, Przemysław Rutkowski, Ewa Słomińska, Ryszard T Smolenski, Julian Swierczyński
There are almost 100 different substances called uremic toxins. Nicotinamide derivatives are known as new family of uremic toxins. These uremic compounds play a role in an increased oxidative stress and disturbances in cellular repair processes by inhibiting poly (ADP-ribose) polymerase activity. New members of this family were discovered and described. Their toxic properties were a subject of recent studies. This study evaluated the concentration of 4-pyridone-3-carboxamid-1-β-ribonucleoside-triphosphate (4PYTP) and 4-pyridone-3-carboxamid-1-β-ribonucleoside-monophosphate (4PYMP) in erythrocytes of patients with chronic renal failure...
January 2012: Journal of Renal Nutrition
Marica Cariello, Simona Simone, Antonia Loverre, Margherita Gigante, Francesca Incampo, Stefania Pietanza, Mario Colucci, Francesco P Schena, Loreto Gesualdo, Giuseppe Grandaliano, Giovanni Pertosa
AIMS: This study investigated on (i) the role of gp91(phox)/NOX2 in reactive oxygen species (ROS) generation in hemodialysis (HD) patients, and (ii) the link between clotting activation and ROS production in this setting. RESULTS: The study was performed on peripheral blood mononuclear cells (PBMCs) isolated from HD patients randomized to polysulphon/polyamide (S-group, n=30) or ethylene-vinyl-alcohol (EVAL) membrane (E-group, n=30) treatment and from healthy subjects (control group, n=15)...
March 1, 2012: Antioxidants & Redox Signaling
J Vasantha, P Soundararajan, N Vanitharani, G Kannan, P Thennarasu, G Neenu, C Umamaheswara Reddy
Hyperphosphatemia is an important modifiable risk factor for death and cardiovascular events in patients on hemodialysis (HD). As nicotinamide has been shown as an inhibitor of sodium-dependent phosphate co-transport in rat renal tubule and small intestine, we examined whether nicotinamide reduces hyperphosphatemia in patients undergoing HD. The study was conducted in 30 end-stage renal disease (ESRD) patients [20 (66.7%) males and 10 (33.3%) females; mean age 54 ± 14.9 years] undergoing twice/thrice weekly HD for more than 3 months...
October 2011: Indian Journal of Nephrology
Heshmatolah Shahbazian, Azita Zafar Mohtashami, Ali Ghorbani, Mohammad Reza Abbaspour, Sayed Seifolah Belladi Musavi, Fatemeh Hayati, Ghollam Reza Lashkarara
BACKGROUND: Recently, nicotinamide has been suggested as an effective drug for hyperphosphatemia in hemodialysis patients. The authors assessed the efficacy and safety of nicotinamide in these patients with lower doses and longer duration than other studies. METHODS: Forty eight patients with fasting serum phosphorus >5 mg/dl enrolled in this randomized clinical trial study and were randomly assigned to two equal-sized groups of nicotinamide or placebo. The study lasted 8 weeks...
2011: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
Chiu-Yeh Tsai, Su-Chu Lee, Chi-Chih Hung, Jia-Jung Lee, Mei-Chuan Kuo, Shang-Jyh Hwang, Hung-Chun Chen
OBJECTIVE: False elevation of blood glucose levels measured by glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ)-based glucose self-monitoring systems; glucometer) in peritoneal dialysis (PD) patients using icodextrin solution has been well documented. However, adverse hypoglycemic events caused by misreadings for blood glucose are still being reported. We aimed to study blood glucose levels measured simultaneously using different methods in PD patients with switching of icodextrin, and throughout daily exchanges either using icodextrin or not...
May 2010: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Leszek Niepolski, Alicja E Grzegorzewska, Monika Młot-Michalska
BACKGROUND/AIMS: To examine plasma levels of visfatin and endogenous secretory receptor for advanced glycation end-products (esRAGE) in diabetic and non-diabetic patients treated with intermittent hemodialysis (IHD), and to explore the possible associations between them, insulin resistance evaluated by homeostasis model assessment for insulin resistance (HOMA-IR), as well as selected biochemical and anthropometric parameters. METHODS: The study was carried out in 65 IHD patients...
June 2010: International Urology and Nephrology
Akihiko Kato, Mari Odamaki, Junko Ishida, Akira Hishida
Pre-B cell colony-enhancing factor (PBEF)/visfatin is produced by adipose tissue, skeletal muscle, bone marrow, the liver and lymphocytes. Although serum PBEF/visfatin is related to the pathogenesis of atherosclerosis, and its level is elevated in patients with chronic kidney disease, it remains unclear whether increased PBEF/visfatin is associated with atherosclerotic parameters in hemodialysis (HD) patients. In this study, we measured serum PBEF/visfatin in 68 chronic HD patients (age 66 +/- 14 years, time on HD 76 +/- 76 months, 41 males, 27 females) and examined the association of serum PBEF/visfatin with serum asymmetric dimethylarginine, arteriosclerotic parameters such as pulse wave velocity, ankle brachial pressure index and the percent of abdominal aortic wall calcification in a cross-sectional fashion...
2009: American Journal of Nephrology
Yasemin Erten, Fatma Ayerden Ebinç, Haksun Ebinç, Hatice Paşaoğlu, Canan Demirtaş, Gülten Taçoy, Eyüp Koç, Ulver Derici, Kadriye Altok Reis, Musa Bali, Turgay Arinsoy, Sükrü Sindel
Visfatin was recently defined as an adipocytokine; however, the pathophysiological role of visfatin is not completely understood. A few studies suggest that visfatin may be a new proinflammatory adipocytokine. The aim of the present study was to compare serum visfatin levels between hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) patients and evaluate the relationship between visfatin levels to IL-6, TNF-alpha, and left ventricular hypertrophy. Serum visfatin, IL-6, and TNF-alpha levels were measured by using the ELISA method, and echocardiographic evaluations were performed in 31 hemodialysis patients, 30 CAPD patients, and 21 healthy volunteers...
2008: Renal Failure
Philippe Rieu
Hyperphosphatemia plays a key role in the development of hyperparathyroidism and extraosseous calcification and is associated with increased mortality in hemodialysis patients. The treatment of hyperphosphatemia therefore represents a cornerstone in the management of dialyzed patients. NFK-KDOQI 2003 has recommended rigorous control of serum phosphorus to between 1.13-1.78 mmol/l. A multiple-factor approach can be used to reduce serum phosphate: 1) reduce phosphorous intake in the diet; 2) increase phosphate removal by dialytic treatment; 3) use old and new phosphate binders; 4) treat with nicotinamide; and 5) control serum parathyroid hormone levels...
December 2005: Néphrologie & Thérapeutique
Matthieu Monge, Irina Shahapuni, Roxana Oprisiu, Najeh El Esper, Philippe Morinière, Ziad Massy, Gabriel Choukroun, Albert Fournier
The 2003 guidelines for the management of hyperparathyroidism in chronic kidney disease compiled by the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation (NKF-K/DOQI) were formulated on the basis of work published up until 2001. Since then, new drugs (e.g. calcimimetics and lanthanum carbonate) have become available, and others (e.g. sevelamer, nicotinamide and paricalcitol) have been more stringently clinically evaluated. Because of these advancements, a reappraisal of the 2003 guidelines is justified...
June 2006: Nature Clinical Practice. Nephrology
Krishnaswamy Sampathkumar, Manickam Selvam, Yesudas Santhakumari Sooraj, Sankaran Gowthaman, Rajappan Nair Prabha Ajeshkumar
BACKGROUND: Hyperphosphatemia is common in hemodialysis patients. Recent animal studies show that nicotinamide inhibits the sodium dependent phosphate co-transport in the small intestine and thereby reduces serum phosphorus levels. Nicotinic acid which is the prodrug of nicotinamide is widely used as antihyperlipidemic agent. We examined in a prospective study whether it reduces serum phosphorus levels in hemodialysis patients. METHODS: Patients who were on maintenance hemodialysis were enrolled in to the study if their predialysis serum phosphorus was more than 6 mg/dl...
2006: International Urology and Nephrology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"